Appropriate Use of IV Amoxicillin After Recent Oral Co-amoxiclav Treatment

Introduction to Antibiotic Selection

The Infectious Diseases Society of America suggests that if the patient required co-amoxiclav initially, this implies either empiric coverage for beta-lactamase producers or documented infection with such organisms 1, 2.

The American College of Clinical Pharmacology recommends continuing beta-lactamase inhibitor coverage with IV ampicillin-sulbactam (1.5-3 g IV q6h) or IV amoxicillin-clavulanate if available in the setting 3, 4.
The Infectious Diseases Society of America advises that alternative IV regimens depend on the specific infection site and severity, but should maintain or broaden coverage rather than narrow it 5, 6.

The American College of Clinical Pharmacology suggests that IV amoxicillin monotherapy could be considered only if culture results definitively identify a pathogen susceptible to amoxicillin alone (e.g., Streptococcus species, Enterococcus faecalis) with documented susceptibility testing 5.
The Infectious Diseases Society of America recommends that IV amoxicillin monotherapy could be considered if the patient is improving on oral co-amoxiclav and IV access is needed temporarily for other reasons, with a plan to return to oral co-amoxiclav once feasible 7.

The decision algorithm should identify why IV therapy is now needed (clinical deterioration, NPO status, severe infection, absorption concerns) 5.
The Infectious Diseases Society of America suggests reviewing any available culture data - if organisms are susceptible to amoxicillin alone, monotherapy may be appropriate 5.
The American College of Clinical Pharmacology advises maintaining beta-lactamase inhibitor coverage with IV ampicillin-sulbactam or considering broader spectrum agents depending on infection severity 3, 4, 5.
The Infectious Diseases Society of America recommends continuing appropriate antibiotics for the full treatment duration even if this extends beyond neutrophil recovery or clinical improvement 5, 6.